In-Vivo Study of Dipyridamole Liquisolid Compacts
Main Article Content
Keywords
Dipyridamole, Liquisolid, Factorial, AUC, Cmax, Tmax
Abstract
The purpose of this study was to employ a 32-factorial design to develop and assess dipyridamole liquisolid compacts. An in vivo study was conducted in albino Wistar rats to determine the pharmacokinetic parameters for the optimized formulation. Dipyridamole plasma concentration-time data pharmacokinetic analysis yielded the following pharmacokinetic parameters: Cmax values ranging from 511.77 ± 10.18 ng/mL to 621.16 ±14.32 ng/mL; Tmax values ranging from 1.25 ± 0.03 to 0.75 ± 0.02 hours; and AUC values ranging from 2332.90 ± 112.10 h.ng/mL to 2059.80 ± 124.42 h.ng/mL. Results obtained for the formulated product prepared with liquid-solid compacts technology show rapid release in comparison to the conventional formulation showing variability in pharmacokinetic parameters.
References
2. S. G. Kapsi and J. W. Ayres, “Processing factors in development of solid solution formulation of itraconazole for enhancement of drug dissolution and bioavailability,” International Journal of Pharmaceutics, vol. 229, no. 1-2, pp. 193–203, 2001.
3. Y. Javadzadeh, B. Jafari-Navimipour, and A. Nokhodchi, “Liquisolid technique for dissolution rate enhancement of a high dose water-insoluble drug (carbamazepine),” International Journal of Pharmaceutics, vol. 341, no. 1-2, pp. 26–34, 2007.
4. Nokhodchi, Y. Javadzadeh, M. R. Siahi-Shadbad, and M. Barzegar-Jalali, “The effect of type and concentration of vehicles on the dissolution rate of a poorly soluble drug (indomethacin) from liquisolid compacts,” Journal of Pharmacy and Pharmaceutical Sciences, vol. 8, no. 1, pp. 18–25, 2005.
5. S. Spireas, S. Sadu, and R. Grover, “In vitro evaluation of hydrocortisone liquisolid tablets,” Journal of Pharmaceutical Sciences, vol. 87, no. 7, pp. 867–872, 1998.
6. "Dipyridamole" at Dorland's Medical Dictionary
7. Brown DG, Wilkerson EC, Love WE (March 2015). "A review of traditional and novel oral anticoagulant and antiplatelet therapy for dermatologists and dermatologic surgeons". Journal of the American Academy of Dermatology. 72 (3): 524–34.
8. G.R.Prasanna Laxmi, P.Shashikala, “Enhancing the solubility of Dipyridamole by Liquisolid Compacts based on Factorial design approach”, Journal of Pharmaceutical Negative Results; Volume 13; Special Issue 6; 2022; 1149-1166.
9. OECD Guideline for Testing of Chemicals: Acute Dermal Irritation, Corrosion, revised version, Guideline No. 404, adopted May 1981.OECD, Rome, Italy.
10. Guide for care and use of laboratory animals: Public Health Service: National Institutes of Health NIH Publication No. 86-23 Revised 1985.
11. Ting Qin, Feng Qin, Ning Li, Shan Lu, Wei Liu and Famei Li; Quantitative determination of dipyridamole in human plasma by high-performance liquid chromatography–tandem mass spectrometry and its application to a pharmacokinetic study; Biomed. Chromatogr. 2010; 24: 268–273.
12. USFDA (2003): Guidance for Industry: Bioavailability and bioequivalence studies for orally administered drug products-General considerations. US Department of Health and Human Services: Food and Drug Administration: Centre for Drug Evaluation and Research (CDER), Rockville, MD. www.fda.gov/cder/guidance/index.html
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.